Abstract Introduction Treatment recommendations for Peyronie's Disease (PD) differ based
on whether a patient is in the acute/active versus chronic/stable phase of the disease, yet …

Introduction Current clinical guidelines on Peyronie's disease (PD) advocate non-surgical
treatment options as the first-line therapy despite inconsistent clinical outcomes when …

The tunica albuginea (TA) of the penis is an elastic layer that serves a structural role in
penile erection. Disorders affecting the TA cause pain, deformity, and erectile dysfunction …

ABSTRACT Introduction Collagenase Clostridium histolyticum (CCH) is an injectable agent
used to treat Peyronie's disease (PD) by enzymatically degrading the interstitial collagen in …

Background In the original clinical trials evaluating intralesional collagenase Clostridium
histolyticum for Peyronie disease (PD), treatment protocols were limited to 8 injections. Aim …

Introduction Peyronie's disease (PD) is an inflammatory disorder of the tunica albuginea
causing fibrotic changes including abnormal penile curvature, pain, and erectile dysfunction …

Background Peyronie's disease (PD) can be subdivided into acute and chronic phases.
Intralesional collagenase Clostridium histolyticum has been shown to improve curvature in …

Abstract Introduction Collagenase Clostridium histolyticum (CCH) remains the only Food
and Drug Administration–approved medical treatment for Peyronie's disease (PD). The …

Purpose: The safety label for collagenase Clostridium histolyticum was updated to include
postinjection acute lower back pain as an adverse event observed with intralesional therapy …

Peyronie's disease (PD) deformity comes in various shapes and sizes: curvature,
shortening, and what is referred to as “volume loss deformity”(VLD). 1 VLD are focal or more …